- Email: [email protected]
Correction to Lancet Haematol 2017; 4: e362–73
Corrections
Correction to Lancet Haematol 2017; 4: e362–73 Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4: e362–73—In the fourth paragraph of the Results, “one-sided 97·5% CI 4·25%” should have been “one-sided 97·5% CI –4·25%”. This correction has been made to the online version as of July 25, 2017, and the printed Article is correct.
www.thelancet.com/haematology Published online July 25, 2017 http://dx.doi.org/10.1016/S2352-3026(17)30139-4
Published Online July 25, 2017 http://dx.doi.org/10.1016/ S2352-3026(17)30139-4
e1
Correction to Lancet Haematol 2017; 4: e362–73 Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4: e362–73—In the fourth paragraph of the Results, “one-sided 97·5% CI 4·25%” should have been “one-sided 97·5% CI –4·25%”. This correction has been made to the online version as of July 25, 2017, and the printed Article is correct.
www.thelancet.com/haematology Published online July 25, 2017 http://dx.doi.org/10.1016/S2352-3026(17)30139-4
Published Online July 25, 2017 http://dx.doi.org/10.1016/ S2352-3026(17)30139-4
e1